Amicus Retained Earnings vs Non Current Assets Total Analysis
FOLD Stock | USD 9.99 0.26 2.54% |
Amicus Therapeutics financial indicator trend analysis is way more than just evaluating Amicus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amicus Therapeutics is a good investment. Please check the relationship between Amicus Therapeutics Retained Earnings and its Non Current Assets Total accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
Retained Earnings vs Non Current Assets Total
Retained Earnings vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amicus Therapeutics Retained Earnings account and Non Current Assets Total. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Amicus Therapeutics' Retained Earnings and Non Current Assets Total is -0.28. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Amicus Therapeutics, assuming nothing else is changed. The correlation between historical values of Amicus Therapeutics' Retained Earnings and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Amicus Therapeutics are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Retained Earnings i.e., Amicus Therapeutics' Retained Earnings and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | -0.28 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Amicus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amicus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.At present, Amicus Therapeutics' Issuance Of Capital Stock is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 4.6 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.19.
2023 | 2024 (projected) | Extraordinary Items | 90K | 85.5K | Reconciled Depreciation | 7.0M | 6.3M |
Amicus Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Amicus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Amicus Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 850.2M | 886.5M | 905.1M | 724.2M | 777.9M | 451.1M | |
Total Stockholder Equity | 476.4M | 286.4M | 307.4M | 123.0M | 160.2M | 168.7M | |
Retained Earnings | (1.8B) | (2.0B) | (2.3B) | (2.5B) | (2.7B) | (2.5B) | |
Other Assets | 51.3M | 65.4M | 47.4M | 42.2M | 48.6M | 41.8M | |
Common Stock Shares Outstanding | 240.4M | 258.9M | 271.4M | 289.1M | 295.2M | 309.9M | |
Liabilities And Stockholders Equity | 850.2M | 886.5M | 905.1M | 724.2M | 777.9M | 473.3M | |
Other Stockholder Equity | 2.2B | 2.3B | 2.6B | 2.7B | 2.8B | 3.0B | |
Total Liab | 373.8M | 600.1M | 597.8M | 601.1M | 617.7M | 648.6M | |
Other Current Liab | 1.3M | 104.2M | 117.1M | 110.1M | 131.8M | 138.4M | |
Total Current Liabilities | 128.8M | 129.7M | 146.0M | 139.0M | 167.7M | 176.1M | |
Accounts Payable | 120.4M | 17.1M | 21.5M | 15.4M | 15.1M | 21.1M | |
Cash | 142.8M | 163.2M | 245.2M | 148.8M | 247.0M | 259.3M | |
Short Term Investments | 309.9M | 320.0M | 237.3M | 144.8M | 39.2M | 37.2M | |
Other Current Assets | 20.0M | 29.7M | 34.8M | 40.2M | 49.5M | 52.0M | |
Common Stock | 2.6M | 2.7M | 2.8M | 2.8M | 2.9M | 3.1M | |
Property Plant Equipment | 47.7M | 43.9M | 42.5M | 30.8M | 35.4M | 37.2M | |
Short Long Term Debt Total | 210.2M | 441.7M | 440.1M | 452.1M | 445.1M | 467.3M | |
Other Liab | 41.9M | 35.6M | 19.1M | 18.5M | 21.3M | 20.2M | |
Property Plant And Equipment Net | 81.0M | 67.2M | 63.1M | 60.3M | 58.0M | 60.9M | |
Net Debt | 67.4M | 278.5M | 194.9M | 303.3M | 198.1M | 208.0M | |
Non Current Assets Total | 330.1M | 307.1M | 308.3M | 300.4M | 294.8M | 204.5M | |
Non Currrent Assets Other | 28.3M | 19.1M | 24.4M | 10.0M | 15.5M | 16.2M | |
Long Term Debt | 149.5M | 389.3M | 389.4M | 392.0M | 387.9M | 407.3M | |
Cash And Short Term Investments | 452.7M | 483.3M | 482.5M | 293.6M | 286.2M | 251.3M | |
Common Stock Total Equity | 2.6M | 2.7M | 2.8M | 2.8M | 3.2M | 3.4M | |
Non Current Liabilities Total | 245.0M | 470.5M | 451.8M | 462.1M | 450.0M | 243.4M | |
Property Plant And Equipment Gross | 81.0M | 67.2M | 83.0M | 82.6M | 83.4M | 87.6M | |
Total Current Assets | 520.1M | 579.5M | 596.8M | 423.8M | 483.1M | 293.7M | |
Accumulated Other Comprehensive Income | 2.8M | 8.2M | 5.0M | (12.1M) | 5.3M | 5.6M | |
Net Tangible Assets | 255.6M | 65.6M | 86.6M | (97.8M) | (112.4M) | (106.8M) | |
Net Receivables | 33.3M | 46.9M | 52.7M | 66.2M | 87.6M | 92.0M | |
Retained Earnings Total Equity | (1.8B) | (2.0B) | (2.3B) | (2.5B) | (2.3B) | (2.2B) | |
Capital Surpluse | 2.2B | 2.3B | 2.6B | 2.7B | 3.1B | 1.7B | |
Inventory | 14.0M | 19.6M | 26.8M | 23.8M | 59.7M | 62.7M | |
Deferred Long Term Liab | 14.0M | 12.3M | 10.8M | 9.6M | 8.6M | 8.2M | |
Non Current Liabilities Other | 81.5M | 68.9M | 51.6M | 60.5M | 13.3M | 12.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Revenue Per Share 1.353 | Quarterly Revenue Growth 0.306 | Return On Assets (0.06) | Return On Equity (1.07) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.